CANB logo

Can B Corp. (CANB)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Can B Corp. (CANB) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 38/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.

Zuletzt analysiert: 15. März 2026
38/100 KI-Bewertung

Can B Corp. (CANB) Gesundheitswesen & Pipeline-Uebersicht

CEOMarco Alfonsi
Mitarbeiter12
HauptsitzHicksville, US
IPO-Jahr2012

Can B Corp. focuses on the development, manufacturing, and sale of CBD-based products in the United States, offering a diverse range of hemp-derived products through its website, vending machines, and medical professionals, positioning itself within the competitive and evolving CBD market.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 15. März 2026

Investmentthese

Can B Corp. presents a speculative investment opportunity within the high-growth CBD market. Key value drivers include the expansion of its product line and distribution channels. Growth catalysts include increasing consumer awareness and acceptance of CBD products, as well as potential regulatory changes that could broaden market access. However, the company faces significant risks, including intense competition, evolving regulations, and the need for substantial capital to scale operations. With a market capitalization of $0.00B and a negative P/E ratio of -0.10, the company's financial performance requires close monitoring. Investors should carefully consider the risks and uncertainties associated with this OTC-traded stock.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Can B Corp. operates in the cannabidiol (CBD) market, which is projected to reach billions of dollars in the coming years.
  • The company offers a diversified product line including oils, creams, moisturizers, and concentrates under brands like Canbiola and Nu Wellness.
  • Can B Corp. distributes its products through its website, vending machines, and medical professionals.
  • The company rebranded from Canbiola Inc. to Can B Corp. in February 2020, signaling a strategic focus on the CBD market.
  • Can B Corp. has a beta of 0.85, indicating lower volatility compared to the overall market.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Established brand names (Canbiola, Nu Wellness, etc.)
  • Diverse product line of CBD products
  • Multiple distribution channels (website, vending machines, medical professionals)
  • Focus on hemp-derived CBD products

Schwaechen

  • Limited market capitalization ($0.00B)
  • Negative P/E ratio (-0.10)
  • OTC listing indicates higher risk
  • Small number of employees (12)

Katalysatoren

  • Upcoming: Potential regulatory changes in the CBD market could expand market access and increase demand for Can B Corp.'s products.
  • Ongoing: Increasing consumer awareness and acceptance of CBD products is driving market growth and creating opportunities for Can B Corp.
  • Ongoing: Expansion of distribution channels through partnerships with retailers and healthcare providers could boost sales and market share.

Risiken

  • Potential: Intense competition in the CBD market could erode Can B Corp.'s market share and profitability.
  • Potential: Evolving regulations and regulatory uncertainty could create compliance challenges and increase operating costs.
  • Potential: Fluctuations in hemp prices could impact Can B Corp.'s gross margins.
  • Ongoing: The company's OTC listing indicates higher risk and potential for price volatility.
  • Ongoing: Limited financial disclosure increases the risk for investors.

Wachstumschancen

  • Expansion of Product Line: Can B Corp. can capitalize on the growing CBD market by expanding its product line to include new and innovative formulations, such as CBD-infused beverages, edibles, and pet products. The global CBD market is projected to reach $55.79 billion by 2028, offering significant growth potential. Timeline: Within the next 2-3 years, Can B Corp. can introduce new product lines to cater to evolving consumer preferences.
  • Strategic Partnerships: Forming strategic partnerships with established retailers, distributors, and healthcare providers can significantly expand Can B Corp.'s market reach and brand visibility. Collaborations with major retail chains or online marketplaces can provide access to a wider customer base. Timeline: Can B Corp. should actively pursue partnership opportunities within the next 12-18 months.
  • Geographic Expansion: Expanding into new geographic markets, both domestically and internationally, represents a significant growth opportunity for Can B Corp. The European CBD market, for example, is experiencing rapid growth and offers attractive opportunities for expansion. Timeline: Can B Corp. should conduct market research and develop a phased expansion strategy over the next 3-5 years.
  • Focus on Research and Development: Investing in research and development to develop proprietary CBD formulations and delivery methods can provide a competitive advantage and attract strategic partnerships. Clinical studies and scientific validation can enhance the credibility and market acceptance of Can B Corp.'s products. Timeline: Ongoing investment in R&D is crucial for long-term growth and differentiation.
  • Direct-to-Consumer (DTC) Sales: Strengthening its direct-to-consumer (DTC) sales channels through its website and online marketing efforts can improve Can B Corp.'s profit margins and customer relationships. Investing in e-commerce infrastructure and digital marketing campaigns can drive online sales growth. Timeline: Can B Corp. should prioritize enhancing its DTC capabilities within the next 6-12 months.

Chancen

  • Expanding into new geographic markets
  • Developing new and innovative CBD products
  • Forming strategic partnerships with retailers and distributors
  • Increasing consumer awareness and acceptance of CBD products

Risiken

  • Intense competition in the CBD market
  • Evolving regulations and regulatory uncertainty
  • Fluctuations in hemp prices
  • Potential for negative publicity or product recalls

Wettbewerbsvorteile

  • Brand recognition through its Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil brands.
  • Distribution network including website, vending machines, and medical professionals.
  • Proprietary formulations and product development capabilities.

Ueber CANB

Can B Corp., formerly Canbiola Inc., was founded in 2005 and is headquartered in Hicksville, New York. The company operates within the rapidly evolving cannabidiol (CBD) market, focusing on the development, manufacture, and sale of CBD-based products. These products are derived from hemp and include a variety of formulations such as oils, creams, moisturizers, isolates, gel caps, spa products, concentrates, and lifestyle products. Can B Corp. distributes its products through multiple channels, including its website, vending machines, and partnerships with medical professionals. The company markets its offerings under several brand names, including Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil, targeting a broad consumer base interested in CBD for wellness and therapeutic purposes. The rebranding from Canbiola Inc. to Can B Corp. in February 2020 reflects the company's strategic shift and focus on the CBD market.

Was das Unternehmen tut

  • Develops cannabidiol (CBD) based products.
  • Manufactures CBD products derived from hemp.
  • Sells CBD products in the United States.
  • Offers CBD oils, creams, moisturizers, and other formulations.
  • Distributes products through its website, vending machines, and medical professionals.
  • Markets products under the Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil brands.

Geschaeftsmodell

  • Develops and manufactures CBD products from hemp.
  • Sells products directly to consumers through its website and vending machines.
  • Distributes products through partnerships with medical professionals.

Branchenkontext

Can B Corp. operates within the rapidly expanding CBD market, driven by increasing consumer interest in natural health and wellness products. The market is characterized by intense competition, evolving regulations, and a fragmented landscape of producers and retailers. Companies like Can B Corp. are vying for market share by differentiating themselves through product innovation, branding, and distribution strategies. The industry faces ongoing challenges related to regulatory uncertainty and the need for standardized quality control measures. The company competes with ACNNF (Acreage Holdings), CBDNF (Charlotte's Web Holdings), CIMVF (Columbia Care Inc.), ETRGF (Green Thumb Industries), and IWINF (iAnthus Capital Holdings).

Wichtige Kunden

  • Consumers seeking CBD products for wellness and therapeutic purposes.
  • Medical professionals who recommend or sell CBD products to their patients.
  • Retail customers who purchase CBD products through vending machines.
KI-Zuversicht: 69% Aktualisiert: 15. März 2026

Finanzdaten

Chart & Info

Can B Corp. (CANB) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CANB.

Kursziele

Wall-Street-Kurszielanalyse fuer CANB.

MoonshotScore

38/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von CANB auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: Marco Alfonsi

CEO

Marco Alfonsi serves as the CEO of Can B Corp. His background and prior experience are not detailed in the provided information. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. He manages a team of 12 employees and is focused on growing Can B Corp.'s presence in the CBD market.

Erfolgsbilanz: Due to limited information, Marco Alfonsi's specific achievements and strategic decisions at Can B Corp. cannot be fully assessed. His leadership is focused on navigating the competitive CBD market and expanding the company's product offerings and distribution channels.

CANB OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the OTC market, indicating that Can B Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to stocks listed on national exchanges.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Liquidity assessment for CANB is difficult due to its OTC Other listing. Trading volume may be low, and the bid-ask spread could be wide, making it challenging to buy or sell shares at desired prices. Investors should exercise caution and be aware of the potential for price volatility and illiquidity.
OTC-Risikofaktoren:
  • Limited financial disclosure due to OTC Other listing.
  • Potential for low trading volume and wide bid-ask spreads.
  • Higher risk of price manipulation and fraud.
  • Limited regulatory oversight compared to major exchanges.
  • Uncertainty regarding the company's long-term viability.
Sorgfaltspruefung-Checkliste:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's competitive position and market share.
  • Evaluate the company's regulatory compliance and risk management practices.
  • Monitor the company's trading volume and price volatility.
  • Consult with a qualified financial advisor before investing.
  • Confirm the legitimacy of the company's business operations.
Legitimitaetssignale:
  • Established presence in the CBD market since 2005.
  • Multiple brand names (Canbiola, Nu Wellness, etc.)
  • Distribution through website, vending machines, and medical professionals.

Haeufige Fragen zu CANB

What are the key factors to evaluate for CANB?

Can B Corp. (CANB) currently holds an AI score of 38/100, indicating low score. Key strength: Established brand names (Canbiola, Nu Wellness, etc.). Primary risk to monitor: Potential: Intense competition in the CBD market could erode Can B Corp.'s market share and profitability.. This is not financial advice.

How frequently does CANB data refresh on this page?

CANB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven CANB's recent stock price performance?

Recent price movement in Can B Corp. (CANB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established brand names (Canbiola, Nu Wellness, etc.). Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider CANB overvalued or undervalued right now?

Determining whether Can B Corp. (CANB) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying CANB?

Before investing in Can B Corp. (CANB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding CANB to a portfolio?

Potential reasons to consider Can B Corp. (CANB) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Established brand names (Canbiola, Nu Wellness, etc.). Additionally: Diverse product line of CBD products. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of CANB?

Yes, most major brokerages offer fractional shares of Can B Corp. (CANB) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track CANB's earnings and financial reports?

Can B Corp. (CANB) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CANB earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Limited information available on Can B Corp.'s financials and operations.
  • OTC listing indicates higher risk and potential for price volatility.
  • Analyst coverage is not available for this stock.
Datenquellen

Popular Stocks